jb62 - Sorry it took so long to find the valuation. I'm not very good at navigating this hub.

The most recent time I posted my valuation was 15 Sept 2017 at 12:36am. Heres the link

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/696981-company-valuation/messages/2169530#message 

If you just want the Coles Notes version it's  Low $15.00/shr

                                                                        Mid $39.00/shr

                                                                       High $117.00/shr

My Low, Mid and High valuations will not change as a result of more dilution from the most recent financing by Hepalink as the changes in the number of patients and the cost per year of medication by Dr Kideckel more than compensate for the additional dilution.

My numbers were based on 10 mil patients, $4200 per year cost of medication, between 3% and 64% market penetration and 133 mil shrs outstanding fully diluted.

My mid case is for $5 to $10 billion in annual sales and a selling price of $7 to $8 billion for the company with 200 million shares outstanding fully diluted.

For comparison Dr Kideckel used 18ish mil patients, $5000 per year cost of medication 2% market penetration and I think 175 mil shrs outstanding.

Please feel free to poke as many holes in my analysis as you want with constructive suggestions so that I may change my process if needed.

Valuations are very subjective, I am not an accountant or analyst. I do this for my own purposes. I do own shares of RVX. DYODD

tada